TY - JOUR
T1 - Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
AU - Elmer, G. W.
AU - McFarland, L. V.
AU - Surawicz, C. M.
AU - Danko, L.
AU - Greenberg, R. N.
PY - 1999
Y1 - 1999
N2 - Background: Despite recent interest in therapeutic microorganisms taken orally, little is known about the pharmacodynamics of these agents in a target population of patients with disease. The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy. Methods: Patients with recurrent CDD all received a 10-day standard antibiotic regimen together with 28 days of S. boulardii or placebo. Stool samples were collected from patients at various time points and assayed for S. boulardii. Results: The mean concentration of S. boulardii of patients who recurred was 2.5 x 104 CFU/g compared to 1 x 106 CEU/g in patients that did not recur (P = 0.02). Patients with low yeast concentrations in their stools (< 104/g) recurred more often (14/15, 93%) compared with patients with higher levels (19/35, 54%, P = 0.007). Clearance of S. boulardii was rapid; only 4% had positive stools 3 days after stopping dosing. Conclusions: After chronic dosing of S. boulardii, patients with low stool concentrations had a higher likelihood of recurrence of CDD. Stool concentrations were also lower during periods of diarrhoea. These results show the importance of characterizing the dynamics of a therapeutic microorganism in patients with disease, as kinetic studies in healthy volunteers may not give a true reflection of the disturbed microecology in the disease state.
AB - Background: Despite recent interest in therapeutic microorganisms taken orally, little is known about the pharmacodynamics of these agents in a target population of patients with disease. The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy. Methods: Patients with recurrent CDD all received a 10-day standard antibiotic regimen together with 28 days of S. boulardii or placebo. Stool samples were collected from patients at various time points and assayed for S. boulardii. Results: The mean concentration of S. boulardii of patients who recurred was 2.5 x 104 CFU/g compared to 1 x 106 CEU/g in patients that did not recur (P = 0.02). Patients with low yeast concentrations in their stools (< 104/g) recurred more often (14/15, 93%) compared with patients with higher levels (19/35, 54%, P = 0.007). Clearance of S. boulardii was rapid; only 4% had positive stools 3 days after stopping dosing. Conclusions: After chronic dosing of S. boulardii, patients with low stool concentrations had a higher likelihood of recurrence of CDD. Stool concentrations were also lower during periods of diarrhoea. These results show the importance of characterizing the dynamics of a therapeutic microorganism in patients with disease, as kinetic studies in healthy volunteers may not give a true reflection of the disturbed microecology in the disease state.
UR - http://www.scopus.com/inward/record.url?scp=0033429431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033429431&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.1999.00666.x
DO - 10.1046/j.1365-2036.1999.00666.x
M3 - Article
C2 - 10594402
AN - SCOPUS:0033429431
SN - 0269-2813
VL - 13
SP - 1663
EP - 1668
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 12
ER -